Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying users area

Try for free

Biogen Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Biogen Inc., consolidated cash flow statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net income
Depreciation and amortization
Impairment of intangible assets
Excess and obsolescence charges related to inventory
Acquired in-process research and development
Share-based compensation
Contingent consideration
(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations
Deferred income taxes
(Gain) loss on strategic investments
(Gain) loss on equity method investment
Other
Accounts receivable
Due from anti-CD20 therapeutic programs
Inventory
Accrued expense and other current liabilities
Income tax assets and liabilities
Other changes in operating assets and liabilities, net
Changes in operating assets and liabilities, net
Adjustments to reconcile net income to net cash flows from operating activities
Net cash flow provided by operating activities
Purchases of property, plant and equipment
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Contingent consideration paid related to Fumapharm AG acquisition
Acquisition of Nightstar Therapeutics plc, net of cash acquired
Purchase of Ionis Pharmaceuticals, Inc. stock
Purchase of Sangamo Therapeutics, Inc. stock
Purchase of Denali Therapeutics Inc. stock
Purchase of Sage Therapeutics, Inc. stock
Proceeds from divestiture of Hillerød, Denmark manufacturing operations
Acquired in-process research and development
Acquisitions of intangible assets
Investment in Samsung Bioepis
Proceeds from sales of strategic investments
Other
Net cash flow (used in) provided by investing activities
Purchase of treasury stock
Payments related to issuance of stock for share-based compensation arrangements, net
Repayments of borrowings and premiums paid on debt exchange
Proceeds from borrowings
Repayments of borrowings
Net contribution (distribution) to noncontrolling interests
Net cash contribution to Bioverativ, Inc.
Contingent consideration payments
Other
Net cash flow used in financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of the year
Cash and cash equivalents, end of the year

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Cash flow statement item Description The company
Net cash flow provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Biogen Inc. net cash flow provided by operating activities decreased from 2019 to 2020 and from 2020 to 2021.
Net cash flow (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Biogen Inc. net cash flow (used in) provided by investing activities decreased from 2019 to 2020 but then slightly increased from 2020 to 2021.
Net cash flow used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Biogen Inc. net cash flow used in financing activities increased from 2019 to 2020 and from 2020 to 2021.